PYC Therapeutics Ltd
ASX:PYC

Watchlist Manager
PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd
ASX:PYC
Watchlist
Price: 1.9 AUD Market Closed
Market Cap: 849.7m AUD
Have any thoughts about
PYC Therapeutics Ltd?
Write Note

Intrinsic Value

PYC's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one PYC stock under the Base Case scenario is 1.19 AUD. Compared to the current market price of 1.9 AUD, PYC Therapeutics Ltd is Overvalued by 37%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PYC Intrinsic Value
1.19 AUD
Overvaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
PYC Therapeutics Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PYC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PYC?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
PYC Therapeutics Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about PYC Therapeutics Ltd

Provide an overview of the primary business activities
of PYC Therapeutics Ltd.

What unique competitive advantages
does PYC Therapeutics Ltd hold over its rivals?

What risks and challenges
does PYC Therapeutics Ltd face in the near future?

Has there been any significant insider trading activity
in PYC Therapeutics Ltd recently?

Summarize the latest earnings call
of PYC Therapeutics Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for PYC Therapeutics Ltd.

Provide P/S
for PYC Therapeutics Ltd.

Provide P/E
for PYC Therapeutics Ltd.

Provide P/OCF
for PYC Therapeutics Ltd.

Provide P/FCFE
for PYC Therapeutics Ltd.

Provide P/B
for PYC Therapeutics Ltd.

Provide EV/S
for PYC Therapeutics Ltd.

Provide EV/GP
for PYC Therapeutics Ltd.

Provide EV/EBITDA
for PYC Therapeutics Ltd.

Provide EV/EBIT
for PYC Therapeutics Ltd.

Provide EV/OCF
for PYC Therapeutics Ltd.

Provide EV/FCFF
for PYC Therapeutics Ltd.

Provide EV/IC
for PYC Therapeutics Ltd.

Show me price targets
for PYC Therapeutics Ltd made by professional analysts.

What are the Revenue projections
for PYC Therapeutics Ltd?

How accurate were the past Revenue estimates
for PYC Therapeutics Ltd?

What are the Net Income projections
for PYC Therapeutics Ltd?

How accurate were the past Net Income estimates
for PYC Therapeutics Ltd?

What are the EPS projections
for PYC Therapeutics Ltd?

How accurate were the past EPS estimates
for PYC Therapeutics Ltd?

What are the EBIT projections
for PYC Therapeutics Ltd?

How accurate were the past EBIT estimates
for PYC Therapeutics Ltd?

Compare the revenue forecasts
for PYC Therapeutics Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of PYC Therapeutics Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of PYC Therapeutics Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of PYC Therapeutics Ltd compared to its peers.

Compare the P/E ratios
of PYC Therapeutics Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing PYC Therapeutics Ltd with its peers.

Analyze the financial leverage
of PYC Therapeutics Ltd compared to its main competitors.

Show all profitability ratios
for PYC Therapeutics Ltd.

Provide ROE
for PYC Therapeutics Ltd.

Provide ROA
for PYC Therapeutics Ltd.

Provide ROIC
for PYC Therapeutics Ltd.

Provide ROCE
for PYC Therapeutics Ltd.

Provide Gross Margin
for PYC Therapeutics Ltd.

Provide Operating Margin
for PYC Therapeutics Ltd.

Provide Net Margin
for PYC Therapeutics Ltd.

Provide FCF Margin
for PYC Therapeutics Ltd.

Show all solvency ratios
for PYC Therapeutics Ltd.

Provide D/E Ratio
for PYC Therapeutics Ltd.

Provide D/A Ratio
for PYC Therapeutics Ltd.

Provide Interest Coverage Ratio
for PYC Therapeutics Ltd.

Provide Altman Z-Score Ratio
for PYC Therapeutics Ltd.

Provide Quick Ratio
for PYC Therapeutics Ltd.

Provide Current Ratio
for PYC Therapeutics Ltd.

Provide Cash Ratio
for PYC Therapeutics Ltd.

What is the historical Revenue growth
over the last 5 years for PYC Therapeutics Ltd?

What is the historical Net Income growth
over the last 5 years for PYC Therapeutics Ltd?

What is the current Free Cash Flow
of PYC Therapeutics Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for PYC Therapeutics Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
PYC Therapeutics Ltd

Current Assets 85.6m
Cash & Short-Term Investments 66.9m
Receivables 18m
Other Current Assets 744k
Non-Current Assets 5.6m
PP&E 1.6m
Intangibles 4.1m
Current Liabilities 9.1m
Accounts Payable 7.5m
Accrued Liabilities 1.3m
Other Current Liabilities 316.1k
Non-Current Liabilities 1.6m
Long-Term Debt 803k
Other Non-Current Liabilities 833.1k
Efficiency

Earnings Waterfall
PYC Therapeutics Ltd

Revenue
22.9m AUD
Operating Expenses
-60.4m AUD
Operating Income
-37.6m AUD
Other Expenses
-158k AUD
Net Income
-37.7m AUD

Free Cash Flow Analysis
PYC Therapeutics Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

PYC Therapeutics has made a strong start to 2024, focusing on advancing three first-in-class drugs targeting genetic diseases. The company aims to establish human safety and efficacy profiles for these drugs by the end of 2025, setting the stage for new drug applications by 2028. Recent data revealed promising safety and preliminary efficacy in their RP11 program. PYC is excited about the potential of these drugs to move through late-stage development successfully, with plans for commercial launch in 2028. The company's strategic focus and encouraging early results signal a significant step towards becoming a commercial-stage company.

What is Earnings Call?
Fundamental Scores

PYC Profitability Score
Profitability Due Diligence

PYC Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROIC is Increasing
Exceptional 1-Year Revenue Growth
Positive Revenue Growth Forecast
27/100
Profitability
Score

PYC Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

PYC Solvency Score
Solvency Due Diligence

PYC Therapeutics Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

PYC Therapeutics Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PYC Price Targets Summary
PYC Therapeutics Ltd

Wall Street analysts forecast PYC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PYC is 3.37 AUD with a low forecast of 2.42 AUD and a high forecast of 4.62 AUD.

Lowest
Price Target
2.42 AUD
28% Upside
Average
Price Target
3.37 AUD
77% Upside
Highest
Price Target
4.62 AUD
143% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PYC?

Click here to dive deeper.

Dividends

PYC Therapeutics Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for PYC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PYC Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd

Country

Australia

Industry

Biotechnology

Market Cap

849.7m AUD

Dividend Yield

0%

Description

PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.

Contact

WESTERN AUSTRALIA
Nedlands
Harry Perkins Institute, 6 Verdun St
+61861510992.0
pyctx.com

IPO

2005-03-30

Employees

-

Officers

CEO & Executive Director
Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.)
CFO & Company Secretary
Mr. Andrew Taylor B.Com., C.A.
Company Secretary
Mr. Kevin Ronald Hart B.Com., B.Comm (Hons), C.A., F.C.A.

See Also

Discover More
What is the Intrinsic Value of one PYC stock?

The intrinsic value of one PYC stock under the Base Case scenario is 1.19 AUD.

Is PYC stock undervalued or overvalued?

Compared to the current market price of 1.9 AUD, PYC Therapeutics Ltd is Overvalued by 37%.

Back to Top